MX2014013079A - Metodo in vitro para el diagnostico y vigilancia del cancer. - Google Patents

Metodo in vitro para el diagnostico y vigilancia del cancer.

Info

Publication number
MX2014013079A
MX2014013079A MX2014013079A MX2014013079A MX2014013079A MX 2014013079 A MX2014013079 A MX 2014013079A MX 2014013079 A MX2014013079 A MX 2014013079A MX 2014013079 A MX2014013079 A MX 2014013079A MX 2014013079 A MX2014013079 A MX 2014013079A
Authority
MX
Mexico
Prior art keywords
diagnosis
cells
vitro method
cancer
surveillance
Prior art date
Application number
MX2014013079A
Other languages
English (en)
Inventor
Jirina Bartunková
Radek Spísek
Original Assignee
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio As filed Critical Sotio As
Publication of MX2014013079A publication Critical patent/MX2014013079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método in vitro para el diagnóstico y/o el control y/o predicción del progreso de una enfermedad cancerosa, caracterizado por que se determina, en al menos una muestra, la proporción de células Treg a al menos un grupo diferente de células T que comprende el grupo de células Th17, células Th1 y/o células Th2.
MX2014013079A 2012-07-02 2013-06-27 Metodo in vitro para el diagnostico y vigilancia del cancer. MX2014013079A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20120174539 EP2682750A1 (en) 2012-07-02 2012-07-02 In vitro method for the diagnosis and surveillance of cancer
US201261672941P 2012-07-18 2012-07-18
PCT/EP2013/063448 WO2014005909A1 (en) 2012-07-02 2013-06-27 In vitro method for the diagnosis and surveillance of cancer

Publications (1)

Publication Number Publication Date
MX2014013079A true MX2014013079A (es) 2014-12-08

Family

ID=46397089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013079A MX2014013079A (es) 2012-07-02 2013-06-27 Metodo in vitro para el diagnostico y vigilancia del cancer.

Country Status (18)

Country Link
US (1) US20150337384A1 (es)
EP (2) EP2682750A1 (es)
JP (1) JP2015526709A (es)
KR (1) KR20150035521A (es)
CN (1) CN104364656A (es)
AU (1) AU2013286134A1 (es)
BR (1) BR112014026661A2 (es)
CA (1) CA2872668A1 (es)
CL (1) CL2014002975A1 (es)
EA (1) EA201500080A1 (es)
HK (1) HK1202618A1 (es)
IL (1) IL236197A0 (es)
IN (1) IN2015DN00678A (es)
MX (1) MX2014013079A (es)
PH (1) PH12014502436A1 (es)
SG (1) SG11201406581UA (es)
WO (1) WO2014005909A1 (es)
ZA (1) ZA201409298B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
EP3111221B2 (en) 2014-02-24 2022-01-19 Ventana Medical Systems, Inc. Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3.
JP2017512493A (ja) * 2014-03-14 2017-05-25 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
US20160266125A1 (en) * 2015-03-12 2016-09-15 John Wayne Cancer Institute Methods of treating and predicting progression of cancer based on t cell subsets
CA2990618A1 (en) * 2015-06-22 2016-12-29 Esen SEFIK Induction of lamina propria regulatory t cells
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
CN106932576A (zh) * 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
JP7255896B2 (ja) * 2017-05-19 2023-04-11 ロイヤル・メルボルン・インスティテュート・オブ・テクノロジー シクロホスファミド療法に対する応答者の予測
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108508196B (zh) * 2018-04-13 2020-10-27 何韶衡 一种检测人调节性t细胞亚型的试剂盒及检测方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
FI3820573T3 (fi) 2018-07-10 2023-11-01 Novartis Ag 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa
CN112740042A (zh) * 2018-09-20 2021-04-30 文塔纳医疗***公司 基于大小门控以分析流式细胞术数据

Also Published As

Publication number Publication date
IL236197A0 (en) 2015-01-29
SG11201406581UA (en) 2015-01-29
CL2014002975A1 (es) 2015-04-24
EP2867677A1 (en) 2015-05-06
CA2872668A1 (en) 2014-01-09
US20150337384A1 (en) 2015-11-26
IN2015DN00678A (es) 2015-06-26
JP2015526709A (ja) 2015-09-10
EP2682750A1 (en) 2014-01-08
CN104364656A (zh) 2015-02-18
KR20150035521A (ko) 2015-04-06
BR112014026661A2 (pt) 2017-06-27
PH12014502436A1 (en) 2015-01-12
WO2014005909A1 (en) 2014-01-09
AU2013286134A1 (en) 2015-01-22
ZA201409298B (en) 2015-12-23
EA201500080A1 (ru) 2015-06-30
HK1202618A1 (en) 2015-10-02

Similar Documents

Publication Publication Date Title
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2014028378A3 (en) Methods and systems for detecting biological components
MX2015015532A (es) Metodo y sistema de identificacion de biomarcadores.
EP3262417A4 (en) CELL IMAGING AND ANALYSIS TO DIFFERENTIATE CLINICALLY RELEVANT SUBPOPULATIONS OF CELLS
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EP2641202A4 (en) ANALYTE TESTING METHOD AND SYSTEM WITH NOTIFICATION OF MARKED OR WEAK BEHAVIOR OF ANALYTES
MY175351A (en) Method and kit for measurement of nk cell activity
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
EP3910072A3 (en) Maternal plasma transcriptome analysis by massively parallel rna sequencing
NZ629555A (en) Monocyte biomarkers for cancer detection
MX2013013905A (es) Ensayo de lisil oxidasa homologo 2 y metodo de uso de la misma.
EP2723866A4 (en) METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
EP2972321A4 (en) REAGENTS, SYSTEMS AND METHODS FOR ANALYZING WHITE GLOBLES
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
MX2015015015A (es) Metodo para diagnosticar cancer.
WO2014179737A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
MX2016007148A (es) Metodos de ensayo de beta-glucano.
WO2014198670A3 (en) Methods of viewing and analyzing high content biological data
MX2014014829A (es) Anticuerpos autoinmunes.
GB201107557D0 (en) Method
AU2016231086A8 (en) PD-ECGF as biomarker of cancer
GB201204013D0 (en) Method